Despite mixed evidence for the general population, cumulative research reveals dramatic improvement with convalescent plasma for blood cancer patients, especially when given early.
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
Conventional quality-of-life studies usually don’t measure what’s meaningful to patients.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
A novel patient-centered approach aids the collection of research on a rare cancer.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
